Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.66 |
| ▸ | GAA | P10253 | 2/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.66 |
| ▸ | GLA | P06280 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17661794 | 0.78 | L3MBTL1 (0.64) | ALDH1A1LMNAL3MBTL1 | |
| SCHEMBL14435408 | 0.76 | ALDH1A1 (0.49) | ALDH1A1GAAMEN1GLAKMT2A | |
| SCHEMBL28304110 | 0.74 | KMT2A (0.47) | ALDH1A1MEN1KMT2AL3MBTL1MAPT | |
| SCHEMBL2092093 | 0.73 | ALDH1A1 (0.51) | ALDH1A1GAAMEN1GLAKMT2A | |
| SCHEMBL12513636 | 0.73 | ALDH1A1 (0.47) | ALDH1A1GAAMEN1GLAKMT2A | |
| SCHEMBL6788095 | 0.72 | ALDH1A1 (0.55) | ALDH1A1GAAMEN1GLAKMT2A | |
| SCHEMBL12437163 | 0.72 | ALDH1A1 (0.46) | ALDH1A1GAAMEN1GLAKMT2A | |
| SCHEMBL3703872 | 0.72 | NAMPT (1.00) | ALDH1A1KMT2ALMNA | |
| SCHEMBL40015 | 0.70 | ALDH1A1 (0.46) | ALDH1A1GAAMEN1GLAKMT2A | |
| SCHEMBL8435060 | 0.70 | SLC6A2 (0.55) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9951073-B2 | Compounds and compositions for treating chemical warfare agent-induced injuries | HYDRA BIOSCIENCES, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-20130303521-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES | HYDRA BIOSCIENCES, INC (US) | 2013-11-14 | — | — | US | disclosed |
| US-8163761-B2 | Methods and compositions for treating disorders | HYDRA BIOSCIENCES, INC. (US) | 2012-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303521-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES | ELANE, CASP3, MMP8 | ALDH1A1 1104/4885GAA 1962/4885MEN1 1785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.